Observational Study of Tildrakizumab in Patients With Moderate to Severe Plaque Psoriasis in Routine Clinical Practice
NCT ID: NCT04203693
Last Updated: 2024-07-08
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
331 participants
OBSERVATIONAL
2019-10-30
2024-04-30
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Tilrdakizumab Almirall
NCT07244744
A Study of Tildrakizumab in Pediatric Subjects With Chronic Plaque Psoriasis
NCT03997786
LAS41008 in Moderate to Severe Chronic Plaque Psoriasis
NCT01726933
An Open-Label, Multi-Center Trial in the Treatment of Subjects With Moderate to Severe Plaque Type Psoriasis
NCT00725348
Efficacy, Tolerability and Safety of LAS41004 Formulations in a Psoriasis Plaque Test
NCT02111499
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
CASE_ONLY
PROSPECTIVE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Cohort 1: Tildrakizumab Treated Participants
Participants will be treated with tildrakizumab who have participated in prior tildrakizumab studies
Tildrakizumab
The study physicians will choose the treatment independently of the enrolment in the study according to routine care.
Cohort 2: Newly Tildrakizumab Prescribed Participants
Participants will be newly prescribed tildrakizumab (a prescription has occurred independently of the enrolment in the study)
Tildrakizumab
The study physicians will choose the treatment independently of the enrolment in the study according to routine care.
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Tildrakizumab
The study physicians will choose the treatment independently of the enrolment in the study according to routine care.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Age \>= 18years.
* Moderate to severe chronic plaque psoriasis diagnosis.
* Participants who have participated in Tildrakizumab (Ilumetri®) clinical trials (Cohort 1) OR participants who, according to the physician's therapeutic decision, should start the treatment with Tildrakizumab (Ilumetri®) (Cohort 2).
Exclusion Criteria
18 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Almirall, S.A.
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Study Director
Role: STUDY_DIRECTOR
Almirall, S.A.
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Investigator Site 1
Vienna, , Austria
Investigational site 5
Augsburg, , Germany
Investigational site 10
Berlin, , Germany
Investigational site 11
Berlin, , Germany
Investigational site 13
Berlin, , Germany
Investigational site 8
Erlangen, , Germany
Investigational site 9
Greifswald, , Germany
Investigational site 1
Hamburg, , Germany
Investigational site 2
Hamburg, , Germany
Investigational site 7
Kiel, , Germany
Investigational site 3
Lübeck, , Germany
Investigational site 6
München, , Germany
Investigational site 12
Oberursel, , Germany
Investigational site 4
Quedlinburg, , Germany
Investigational site 6
Catania, , Italy
Investigational site 7
Genova, , Italy
Investigational site 3
Modena, , Italy
Investigational site 4
Parma, , Italy
Investigational site 1
Roma, , Italy
Investigational site 2
Roma, , Italy
Investigational site 5
Roma, , Italy
Investigational site 1
Breda, , Netherlands
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
NIS Study M-14745-43
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.